H. Lundbeck A/S ended the first nine months of 2019 with two acquisitions under its belt and an increase in revenue from four key medicines for neurological disorders. Total revenue for the period was DKK 12.6 billion (€1.7 billion) of which 53% was attributed to the four medicines. However group revenue was down by 9% from a year earlier due to loss of patent protection for Onfi, a treatment for Lennox-Gastaut syndrome. Onfi lost exclusivity in 2018 and sales of the product were DKK 840 million, a decline of 69%.
